Biopharmaceutical company GSK is growing its Massachusetts work force, announcing plans to move its vaccines research and development and infectious disease teams from suburban Maryland to ...

GSK has news on that front today, as well, reporting that the phase 2/3 COSTAR trial of Jemperli with experimental TIM-3 antagonist cobolimab will move into the phase 3 stage on the advice of its ...

First seen in 2023, Tim Foley’s tender play about two brothers grieving for their father, directed by Neil Bettles and Elle While, returns on tour. Jerome Yates plays Tiny, the younger brother ...

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

GSK's business development team have been working overtime of late, with three R&D deals announced in the last few days across Alzheimer's disease and cancer. The Alzheimer's agreement – with ...

GSK meanwhile has previously suggest that the HBV therapy could collectively achieve sales of more than £2 billion ($2.45 billion) at peak, part of a new wave of therapies that it reckons could ...

The FDA has started a review of GSK’s five-in-one meningococcal vaccine, cueing up a decision in mid-February next year, as it tries to chase down a rival candidate from Pfizer cleared last year.

GSK has shifted towards a global marketing model influenced by a Netflix-style approach that aims to match content to the person receiving it. Richard Staines heard about this new strategy at the ...

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...